Purpose: Protease-Activated receptor 2 (PAR2) reportedly triggers the immune response in allergic asthma. We aimed to investigate the mechanism on allergic inflammation mediated by PAR2. Methods: Human lung epithelial cells (A549 cells) were used for in vitro, and the German cockroach extract (GCE)-induced mouse model was developed for in vivo studies. Results: In A549 cells, the levels of reactive oxygen species (ROS) and thymic stromal lymphopoietin (TSLP) were significantly increased by GCE treatment, but were suppressed by PAR2-Antagonist (PAR2-Ant) or N-Acetylcysteine (NAC) treatment. Claudin-1 was degraded by GCE, and was restored by PAR2-Ant or NAC in the cells. In the mouse model, the clinical appearance including bronchial hyperresponsiveness, bronchoalveolar lavage fluid analysis and total immunoglobulin E were significantly suppressed by PAR2-Ant or NAC. Moreover, TSLP levels in the lung were suppressed by the same treatments in the lung. Claudin-1 was also degraded by GCE, and was restored by PAR2-Ant or NAC. Conclusions: ROS generation and epidermal tight junction degradation are triggered by protease, followed by the induction of TSLP in allergic asthma. Our findings could suggest that PAR2-Ant or anti-oxidants could be considered for allergic diseases as preventive alternatives.
CITATION STYLE
Kim, H. J., Lee, S. H., Jeong, S., & Hong, S. J. (2019). Protease-Activated Receptors 2-Antagonist Suppresses Asthma by Inhibiting Reactive Oxygen Species-Thymic Stromal Lymphopoietin Inflammation and Epithelial Tight Junction Degradation. Allergy, Asthma and Immunology Research, 11(4), 560–571. https://doi.org/10.4168/aair.2019.11.4.560
Mendeley helps you to discover research relevant for your work.